Inmune Bio(INMB.US)

Last Updated 19:00:00 ET
longbridge loading

INmune Bio shares are trading higher after the company announced that the FDA granted the fast Track designation to XPro

benzinga_article·
US
INMB
+2.48%
US
BIB
+3.26%
US
PBE
+0.89%
benzinga_article·
US
INMB
+2.48%
US
BIB
+3.26%
US
PBE
+0.89%

Analysts Have Conflicting Sentiments on These Healthcare Companies: Inmune Bio (INMB) and Joint (JYNT)

businessinsider·
US
JYNT
+0.92%
US
INMB
+2.48%
US
IHF
-0.45%
businessinsider·
US
JYNT
+0.92%
US
INMB
+2.48%
US
IHF
-0.45%

Inmune Bio | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
INMB
+2.48%
Earnings Watch·
US
INMB
+2.48%

INmune Bio Expands Cord Tissue License for CORDStrom Platform

Tip Ranks·
US
INMB
+2.48%
US
LABU
+8.93%
US
XBI
+2.97%
Tip Ranks·
US
INMB
+2.48%
US
LABU
+8.93%
US
XBI
+2.97%

Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs

benzinga_article·
US
ARKG
+3.27%
US
INMB
+2.48%
US
XBI
+2.97%
benzinga_article·
US
ARKG
+3.27%
US
INMB
+2.48%
US
XBI
+2.97%

Inmune Bio Earnings Call Balances Progress and Risk

Tip Ranks·
US
XBI
+2.97%
US
BIB
+3.26%
US
LABU
+8.93%
Tip Ranks·
US
XBI
+2.97%
US
BIB
+3.26%
US
LABU
+8.93%
© 2026 Longbridge｜Disclaimer